胃和结直肠原发性印戒细胞癌的免疫组织化学研究：II. MUC1、MUC2、MUC5AC和MUC6在正常黏膜及42例病例中的表达
An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: II. Expression of MUC1, MUC2, MUC5AC, and MUC6 in normal mucosa and in 42 cases.
作者信息
Terada Tadashi
机构信息
Department of Pathology, Shizuoka City Shimizu Hospital, Shizuoka, Japan.
出版信息
Int J Clin Exp Pathol. 2013;6(4):613-21. Epub 2013 Mar 15.
Expression of MUC apomucins has rarely been investigated in the signet-ring cell carcinoma (SRCC) of the stomach and colorectum. The author examined immunohistochemically the expression status of MUC1, MUC2, MUC5AC, and MUC6 in 30 cases of gastric SRCC and 12 cases of colorectal SRCC. The normal distribution of these MUC apomucins was also examined in the non-tumorous parts of the stomach and colorectum. In normal tissues, the stomach epithelial cells consistently expressed MUC2, MUC5AC, MUC6, but consistently not MUC1. In colorectum, cryptal epithelial cells consistently expressed MUC2, but consistently not MUC1, MUC5AC, and MUC6. The expression pattern of the gastric SRCC was as follows: MUC1, 3/30 (10%); MUC2, 4/30 (13%); MUC5AC, 20/30 (67%), and MUC6 21/30 (70%). The expression pattern of the colorectal SRCC was as follows: MUC1, 5/12 (42%); MUC2, 11/12 (92%); MUC5AC, 4/12 (33%); and MUC6, 0/12 (0%). Significant differences (p<0.05) were found in the expression of MUC1 (stomach SRCC 10% vs colorectal SRCC 42%), MUC2 (13% vs 92%), MUC5AC (67% vs 33%), and MUC6 (70% vs 0%). Thus, there was a significant tendency that primary gastric SRCC express MUC5AC and MUC6 but not MUC1 and MUC2, while primary colorectal SRCC express MUC1, MUC2 and MUC5A, but not MUC6. These different expressions of these MUC apomucins in gastric and colorectal SRCC seem useful to determine the primary site of metastatic SRCC and for differential diagnosis of SRCC of other sites. In the gastric SRCC, the up-regulation of MUC1 and the down-regulation of MUC2, MUC5AC and MUC6 appear to be associated with carcinogenesis, malignant potential, progression, and clinical behaviors in gastric SRCC. In the colorectal SRCC, the up-regulation of MUC1 and MUC5AC may be associated with carcinogenesis, malignant potential, progression, and clinical behaviors in colorectal SRCC. A comparative review of the present SRCC and presently reported ordinary adenocarcinoma and SRCC cases of the stomach and colorectum was performed.
胃和结直肠印戒细胞癌（SRCC）中粘蛋白脱辅基蛋白的表达鲜有研究。作者采用免疫组化方法检测了30例胃SRCC和12例结直肠SRCC中MUC1、MUC2、MUC5AC和MUC6的表达情况。同时也检测了这些粘蛋白脱辅基蛋白在胃和结直肠非肿瘤部位的正常分布。在正常组织中，胃上皮细胞持续表达MUC2、MUC5AC、MUC6，但始终不表达MUC1。在结直肠中，隐窝上皮细胞持续表达MUC2，但始终不表达MUC1、MUC5AC和MUC6。胃SRCC的表达模式如下：MUC1，3/30（10%）；MUC2，4/30（13%）；MUC5AC，20/30（67%），MUC6 21/30（70%）。结直肠SRCC的表达模式如下：MUC1，5/12（42%）；MUC2，11/12（92%）；MUC5AC，4/12（33%）；MUC6，0/12（0%）。在MUC1（胃SRCC 10% vs结直肠SRCC 42%）、MUC2（13% vs 92%）、MUC5AC（67% vs 33%）和MUC6（70% vs 0%）的表达上发现了显著差异（p<0.05）。因此，有显著趋势表明原发性胃SRCC表达MUC5AC和MUC6，但不表达MUC1和MUC2，而原发性结直肠SRCC表达MUC1、MUC2和MUC5A，但不表达MUC6。这些粘蛋白脱辅基蛋白在胃和结直肠SRCC中的不同表达似乎有助于确定转移性SRCC的原发部位以及用于其他部位SRCC的鉴别诊断。在胃SRCC中，MUC1的上调以及MUC2、MUC5AC和MUC6的下调似乎与胃SRCC的致癌作用、恶性潜能、进展及临床行为相关。在结直肠SRCC中，MUC1和MUC5AC的上调可能与结直肠SRCC的致癌作用、恶性潜能、进展及临床行为相关。对目前的SRCC以及目前报道的胃和结直肠普通腺癌及SRCC病例进行了比较综述。
Zotero 插件